Saturday 17 October 2026
Export TLPH’s income statement to Excel — free account
Talphera, Inc.
TLPH Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, revenue fell 99.6%, EPS grew 40.0% and free cash flow fell 33.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years; insiders bought in the last twelve months.
1.08
0.01
+0.93%
Follow TLPH
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | — | 86.60 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (14.70) | |
P/B ratio |
— | — | — | 1.92 | |
Price to Tangible BV |
— | — | — | 1.92 | |
EV/Sales |
— | — | — | 51.56 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (1.96) | |
EV/FCF |
— | — | — | (2.57) | |
Quick Ratio |
4.08 | 5.24 | 5.35 | 6.63 | |
Current Ratio |
4.29 | 5.30 | 5.49 | 6.83 | |
Net Debt/EBITDA |
4.19 | 5.24 | 5.70 | 6.22 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.02 | |
Operating CF/Net income |
0.91 | 1.33 | 0.65 | 0.57 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 180,300.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 162,000.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 15,200.00% | |
Graham Net Nets |
— | — | — | 0.28 | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (42.70%) | |
Free Cash Flow Yield |
— | — | — | (23.20%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.05) | (0.05) | (0.06) | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.05) | (0.06) | (0.06) | |
Cash per Share |
0.23 | 0.30 | 0.48 | 0.51 | |
Shareholders Equity per Share |
0.19 | 0.26 | 0.40 | 0.46 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.19 | 0.26 | 0.40 | 0.46 | |
Free Cash Flow |
(3.92) | (3.40) | (2.44) | (2.51) | |
Working Capital |
13.80 | 17.31 | 17.09 | 18.71 | |
Net Current Asset Value |
5.59 | 9.66 | 8.22 | 10.36 | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
— | — | — | 0.00 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
0.61 | 0.63 | 0.61 | 0.46 | |
Average Assets |
21.66 | 22.58 | 23.98 | 25.88 | |
Average Common Equity |
10.52 | 12.04 | 12.52 | 14.41 |
Columns are period end dates